| 臺大學術典藏 |
2022-05-10T08:10:07Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-05-03T02:20:50Z |
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
|
Wasan H.S.; Gibbs P.; Sharma N.K.; Taieb J.; Heinemann V.; Ricke J.; Peeters M.; Findlay M.; Weaver A.; Mills J.; Wilson C.; Adams R.; Francis A.; Moschandreas J.; Virdee P.S.; Dutton P.; Love S.; Gebski V.; Gray A.; Bateman A.; Blesing C.; Brown E.; Chau I.; Cummins S.; Cunningham D.; Falk S.; Hadaki M.; Hall M.; Hickish T.; Hornbuckle J.; Lofts F.; Lowndes S.; Mayer A.; Metcalfe M.; Middleton G.; Montazeri A.; Muirhead R.; Polychronis A.; Purcell C.; Ross P.; Sharma R.A.; Sherwin L.; Smith D.; Soomal R.; Swinson D.; Walther A.; Wilson G.; Amin P.; Angelelli B.; Balosso J.; Beny A.; Bloomgarden D.; Boucher E.; Bruch H.-R.; Bui J.; Burge M.; Cardaci G.; Carlisle J.; Chai S.; Chen Y.-J.; Chevallier P.; Chuong M.; Clarke S.; Coveler A.; Craninx M.; Delanoit T.; Deleporte A.; Eliadis P.; Facchini F.; Ferguson T.; Ferrante M.; Frenette G.; Frick J.; Ganju V.; Garofalo M.; Geboes K.; Gehbauer G.; George B.; Geva R.; Gordon M.; Gregory K.; Gulec S.; Hannigan J.; van Hazel G.; Heching N.; Helmberger T.; Hendlisz A.; Hendrickx K.; Holtzman M.; Isaacs R.; Jackson C.; James P.; Kaiser A.; Karapetis C.; Kaubisch A.; Ko Y.-D.; Kr?ning H.; Lammert F.; Liauw W.; Limentani S.; Louafi S.; de Man M.; Margolis J.; Martin R.; Martoni A.; Marx G.; Matos M.; Monsaert E.; Moons V.; Nott L.; Nusch A.; O'Donnell A.; Ozer H.; Padia S.; Pavlakis N.; Perez D.; Pluntke S.; Polus M.; Powell A.; Pracht M.; Price T.; Ransom D.; Rebischung C.; Ridwelski K.; Riera-Knorrenschild J.; Riess H.; Rilling W.; Robinson B.; Rodr?guez J.; Sanchez F.; Sauerbruch T.; Savin M.; Scheidhauer K.; Schneiderman E.; Seeger G.; Segelov E.; Schmueli E.S.; Shani A.; Shannon J.; Shibata S.; Singhal N.; Smith D.; Smith R.; Stemmer S.; St?tzer O.; Strickland A.; Tatsch K.; Terrebonne E.; Tichler T.; Vehling-Kaiser U.; Vera-Garcia R.; Vogl T.; Walpole E.; Wang E.; Whiting S.; Wolf I.; Ades S.; Aghmesheh M.; Auber M.; Ayala H.; Boland P.; Bouche E.; Bowers C.; Bremer C.; Casado A.R.; Cooray P.; Crain M.; De Wit M.; Dowling K.; Durand A.; Faivre S.; Feeney K.; Ferru A.; Fragoso M.; Granetto C.; Hammel P.; Issacs R.; Iyer R.; Kim Y.H.; JIN-TUNG LIANG; Lim L.; Liu J.H.; Masi G.; Mosconi S.; Numico G.; Ratner L.; Sae-Won H.; Singh M.; Stoltzfus P.; Tan I.; Trogu A.; Underhill C.; Westcott M.; FOXFIRE trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, FOXFIRE-Global trial investigators |
| 臺大學術典藏 |
2021-05-03T02:20:45Z |
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies
|
Gibbs P.; Heinemann V.; Sharma N.K.; Taieb J.; Ricke J.; Peeters M.; Findlay M.; Robinson B.; Jackson C.; Strickland A.; Gebski V.; Van Buskirk M.; Zhao H.; van Hazel G.; Brown M.; Burge M.; Cardaci G.; Clarke S.; Eliadis P.; Ferguson T.; Ganju V.; James P.; Karapetis C.; Liauw W.; Marx G.; Matos M.; Nott L.; Pavlakis N.; Powell A.; Price T.; Ransom D.; Segelov E.; Shannon J.; Singhal N.; Walpole E.; Craninx M.; Delaunoit T.; Deleporte A.; Ferrante M.; Geboes K.; Hendlisz A.; Hendrickx K.; De Man M.; Monsaert E.; Moons V.; Polus M.; Boucher E.; Balosso J.; Chevallier P.; Louafi S.; Pracht M.; Rebischung C.; Smith D.; Terrebonne E.; Bruch H.-R.; Gehbauer G.; Helmberger T.; Ko Y.-D.; Kr?ning H.; Lammert F.; Nusch A.; Pluntke S.; Ridwelski K.; Riera-Knorrenschild J.; Riess H.; Riera J.R.; Sauerbruch T.; Scheidhauer K.; St?tzer O.; Tatsch K.; Vehling-Kaiser U.; Vogl T.; Beny A.; Geva R.; Shacham-Shmueli E.; Stemmer S.; Tichler T.; Wolf I.; Angelelli B.; Martoni A.; Findlay M.P.N.; Isaacs R.; O'Donnell A.; Perez D.; Rodr?guez J.; Vera-Garcia R.; Amin P.; Bloomgarden D.; Bui J.; Carlisle J.; Chai S.; Chen Y.-J.; Chuong M.; Coveler A.; Facchini F.; Frenette G.; Frick J.; Garofalo M.; George B.; Gordon M.; Gulec S.; Hannigan J.; Holtzman M.; Kaubisch A.; Kaiser A.; Kooy T.; Limentani S.; Margolis J.; Martin R.; Ozer H.; Padia S.; Rilling W.; Savin M.; Schneiderman E.; Seeger G.; Shibata S.; Smith R.; Wang E.; Whiting S.; Aghmesheh M.; Cooray P.; Feeney K.; Lim L.; Singh M.; Underhill C.; Durand A.; Faivre S.; Ferru A.; Hammel P.; Bremer C.; De Wit M.; Ayala H.; Heching N.; Shani A.; Granetto C.; Masi G.; Mosconi S.; Numico G.; Trogu A.; Kim Y.H.; Sae-Won H.; Fragoso M.; Tan I.; Casado A.R.; JIN-TUNG LIANG; Liu J.H.; Ades S.; Auber M.; Boland P.; Bowers C.; Crain M.; Dowling K.; Iyer R.; Ratner L.; Sanchez F.; Stoltzfus P.; Westcott M.; SIRFLOX; FOXFIRE Global Trial Investigators |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
|
Lee C.K;Brown C;Gralla R.J;Hirsh V;Thongprasert S;Tsai C.-M;Tan E.H;Ho J.C.-M;Chu D.T;Zaatar A;Osorio Sanchez J.A;Vu V.V;Au J.S.K;Inoue A;Lee S.M;Gebski V;Chih-Hsin Yang; Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:53Z |
Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis
|
Chih-Hsin Yang;Gralla R.J;Gebski V;Links M;Pavlakis N;Rosell R;Mitsudomi T;Zhou C;Inoue A;Lord S.J;Ding P.N;Wu Y.-L;Lee C.K; Lee C.K; Wu Y.-L; Ding P.N; Lord S.J; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla R.J; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non?�Small Cell Lung Cancer?�A Meta-Analysis
|
Chih-Hsin Yang;Mok T;Gebski V;Links M;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Links M; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non?�Small Cell Lung Cancer
|
Lee C.K.; CHIH-HSIN YANG; Gralla R.J; Bray V; Links M; Gebski V; Lord S.J; Lee C.K.;Chih-Hsin Yang;Gralla R.J;Bray V;Links M;Gebski V;Lord S.J;Ding P.N; Ding P.N |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis
|
Chih-Hsin Yang;Mok T;Gralla R.J;Herbst R.S;Gebski V;Links M;Cooper W;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst R.S; Gralla R.J; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer
|
Chih-Hsin Chih-Hsin Yang;Mok T;Gralla R;Gebski V;Davies L;Asher R;Mitsudomi T;Fukuoka M;Rosell R;Sequist L;Wu Y.L;Marschner I;Lord S;Lee C.K; Lee C.K; Lord S; Marschner I; Wu Y.L; Sequist L; Rosell R; Fukuoka M; Mitsudomi T; Asher R; Davies L; Gebski V; Gralla R; Mok T; Chih-Hsin CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
In reply
|
Lee C.K.;Chih-Hsin Yang;Gebski V; Gebski V; CHIH-HSIN YANG; Lee C.K. |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
| 臺大學術典藏 |
2018 |
SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma
|
Ng D.C.E.; Goh B.K.P.; Lo R.H.G.; Tay K.H.; Goh A.S.W.; Low A.S.-C.; Thng C.-H.; Kok K.Y.Y.; Bartlett A.; PO-CHIN LIANG; Chow P.K.H.; Gandhi M.; Tan S.-B.; Khin M.W.; Khasbazar A.; Ong J.; Choo S.P.; Cheow P.C.; Chotipanich C.; Lim K.; Lesmana L.A.; Manuaba T.W.; Yoong B.K.; Raj A.; Law C.S.; Cua I.H.Y.; Lobo R.R.; Teh C.S.C.; Kim Y.H.; Jong Y.W.; Han H.-S.; Bae S.-H.; Yoon H.-K.; Lee R.-C.; Hung C.-F.; Peng C.-Y.; Gebski V.; Mak K.S.W.; Soo K.C.; Liew W.M.; Lekurwale G.; Chow P.K.H.;Gandhi M.;Tan S.-B.;Khin M.W.;Khasbazar A.;Ong J.;Choo S.P.;Cheow P.C.;Chotipanich C.;Lim K.;Lesmana L.A.;Manuaba T.W.;Yoong B.K.;Raj A.;Law C.S.;Cua I.H.Y.;Lobo R.R.;Teh C.S.C.;Kim Y.H.;Jong Y.W.;Han H.-S.;Bae S.-H.;Yoon H.-K.;Lee R.-C.;Hung C.-F.;Peng C.-Y.;Po-Chin Liang;Bartlett A.;Kok K.Y.Y.;Thng C.-H.;Low A.S.-C.;Goh A.S.W.;Tay K.H.;Lo R.H.G.;Goh B.K.P.;Ng D.C.E.;Lekurwale G.;Liew W.M.;Gebski V.;Mak K.S.W.;Soo K.C. |
